HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Resources Pharmaceutical (3320.HK) - Here Are the Concerns

China Healthcare Weekly (Nov.18) - Central Investment Budget, Anesthetic Drugs, Insomniacs Demand

Zhangzhou Pientzehuang Pharmaceutical (600436.CH) - Disappointing Performance Is Just the Beginning

2023 High Conviction - China Healthcare: Recognize the Direction and Follow the Trend

The Future Directions of A-Share After the 20th National Congress of the CPC

China Optimized COVID Policy and Possible Reopen Timeline

Gravity Works As WeWork Doesn't; Now Plan B

Thematic (Sector/Industry)

United states Pharmaceuticals, biotechnology and life sciences / Thematic (Sector/Industry)

<ul>
<li>Xi-Biden meeting could be the most harmonious state both sides can reach for a long time to come - Both sides could draw a red line and then start competing.</li>
<li>Both China and the US hope to pursue absolute security, but like the paradox, the absolute security of one side is the absolute insecurity of the other. </li>
<li>The level of global development is so different that it’s impossible to have the same culture and so-called universal values. The world isn’t a fairy tale, nor is globalization.</li>
</ul>


Xi-Biden meeting could be the most harmonious state both sides can reach for a long time to come - Both sides could draw a red line and then start competing.
Both China and the US hope to pursue absolute security, but like the paradox, the absolute security of one side is the absolute insecurity of the other. 
The level of global development is so different that it’s impossible to have the same culture and so-called universal values. The world isn’t a fairy tale, nor is globalization.


Xi-Biden Meeting and G20 - A Temporary Respite?